TG6002

First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases

20200220 PR FPI 6002.03 EN

By nh|2020-02-20T16:40:21+01:00February 20th, 2020|Press release, TG6002, TG6002|Comments Off

The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism

Johann Foloppe, et al. Molecular Therapy Oncolytics, March 2019 - [...]

By nh|2019-07-01T12:11:36+02:00March 27th, 2019|Publication, TG6002|Comments Off

Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy

Laetitia Fend, et al. Cancer Research, July 2017, DOI: 10.1158/0008-5472.CAN-16-2165 [...]

By alcyon|2019-07-02T10:02:37+02:00July 24th, 2017|Publication, TG6002, TG6002|Comments Off

Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies

Johann Foloppe, et al. XXI International Poxvirus, Asfavirus and Iridovirus [...]

By alcyon|2019-07-02T14:10:18+02:00July 1st, 2016|Publication, TG6002, TG6002|Comments Off